What other stocks do shareholders of Prescient Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prescient Therapeutics investors own include SkyCity Entertainment Group (SKC) and Findi (FND) .

ASX:PTX

Prescient Therapeutics (PTX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free PTX Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 537,831 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 5.88%
Price Target: N/A

Stock Analysis

Get Prescient Therapeutics alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Prescient Therapeutics Stock (ASX:PTX)

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. The company was incorporated in 1986 and is based in Melbourne, Australia.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

PTX Stock News Headlines

April 18, 2024 | msn.com

Prescient Management Expands Portfolio with Additional PMXINC Securities Listing

April 6, 2024 | msn.com

Prescient Management Expands PIPETF Securities in the Market

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 4, 2024 | msn.com

Prescient ETF Expands Offering with Additional Securities Listing

March 26, 2024 | msn.com

Prescient ETF Expands with New Listings in Global Property Portfolio

March 15, 2024 | msn.com

Prescient ETF Expands with New Securities Listing

March 6, 2024 | finance.yahoo.com

We're Hopeful That Prescient Therapeutics (ASX:PTX) Will Use Its Cash Wisely

February 1, 2024 | afr.com

Prescient Therapeutics Limited

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

December 10, 2023 | au.investing.com

Prescient Therapeutics’ PTX-100 Phase 1b study shows excellent safety and promising efficacy in T-cell lymphoma patients

November 20, 2023 | msn.com

MoneyTalks: Prescient set for ‘big pay day’; Aerometrex to grab ‘blue ocean’ AI opportunity

November 16, 2023 | proactiveinvestors.com.au

Prescient Therapeutics nearing a potential payday with PTX-100: Pitt Street Research

November 6, 2023 | au.investing.com

Prescient Therapeutics to participate in prestigious conference; abstract online now

October 31, 2023 | msn.com

Cancer fighter Prescient navigates challenging conditions for biotech, reports strong Q1 FY24

October 17, 2023 | msn.com

Prescient prepares to unveil Phase 1b cancer trial findings at world’s largest haematology conference

October 16, 2023 | proactiveinvestors.com.au

Prescient Therapeutics to present clinical data at prestigious US conference

September 19, 2023 | msn.com

ASX cancer stocks guide: Here’s everything you need to know

August 30, 2023 | msn.com

‘Above and beyond approved therapies’: How Prescient Therapeutics is at the forefront of cancer fighting

June 16, 2023 | finance.yahoo.com

Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference

May 15, 2023 | proactiveinvestors.com.au

Prescient Therapeutics to present CellPryme and OmniCAR data to International Society of Cell and Gene Therapy

May 15, 2023 | proactiveinvestors.com.au

Prescient Therapeutics bolsters board with appointment of experienced US-based pharma executive

April 20, 2023 | finance.yahoo.com

Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

March 16, 2023 | proactiveinvestors.com.au

Prescient Therapeutics' PTX-100 T Cell Lymphoma Phase 1b trial continues to show promising results

March 15, 2023 | msn.com

ASX Health Stocks: High fives as Telix gets expanded FDA approval, Prescient’s PTX-100 returns good results

March 9, 2023 | proactiveinvestors.com.au

Prescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100

March 8, 2023 | msn.com

Guess which ASX biotech stock just rocketed 29% on big FDA news

March 8, 2023 | proactiveinvestors.com

Prescient Therapeutics granted US FDA additional Orphan Drug Designation for PTX-100; shares up

See More Headlines

Receive PTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prescient Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:PTX
CUSIP: N/A
CIK: N/A
Web: www.ptxtherapeutics.com
Phone: 61 3 9692 7222
Fax: N/A
Employees: 171
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,740,000.00
Net Margins: -248.74%
Pretax Margin: N/A
Return on Equity: -32.67%
Return on Assets: -20.79%

Debt

Debt-to-Equity Ratio: 0.81
Current Ratio: 10.26
Quick Ratio: 17.31

Sales & Book Value

Annual Sales: $3.11 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 1.91
Book Value: A$0.03 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 805,320,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.07

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Steven Lee Yatomi-Clarke
MD, CEO & Director
Ms. Melanie Jaye Leydin B.Bus (Age 51)
C.A., CFO & Company Secretary
Comp: $158.4k
Ms. Leanne West
Director of Clinical Affairs & Operations
Dr. Terrence G. Chew (Age 77)
Chief Medical Officer
Comp: $155.99k
Ms. Rebecca Lim
Senior Vice President of Scientific Affairs

Key Competitors

View All Competitors

Insiders

James Campbell
Sold 278,769 shares
Total: $27,319.36 ($0.10/share)

PTX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Prescient Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Prescient Therapeutics investors own include SkyCity Entertainment Group (SKC) and Findi (FND).

This page (ASX:PTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Prescient Therapeutics (PTX) Stock Price, News & Analysis

About Prescient Therapeutics Stock (ASX:PTX)

PTX Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

PTX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info